Advocacy intelligence hub — real-time data for patient organizations
University Hospital, Angers — NA
Novartis Pharmaceuticals — PHASE3
Leslie Thompson — PHASE1, PHASE2
University of Michigan — NA
CHDI Foundation, Inc. — EARLY_PHASE1
BioSensics
Skyhawk Therapeutics, Inc. — PHASE2, PHASE3
Region Skane
University of Virginia — NA
Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
FINANCIAL LANDSCAPE SUMMARY
Total programs
Open now
Foundation grants
Copay cards
Foundation Grants4
Patient Advocate Foundation — Huntington disease
Patient Advocate Foundation
NORD Patient Assistance — Huntington disease
NORD Patient Assistance
PAN Foundation — Huntington disease
PAN Foundation
The Assistance Fund — Huntington disease
The Assistance Fund
Copay Assistance2
Ingrezza
Neurocrine Biosciences Inc.
Xenazine
Lundbeck
Ingrezza
(valbenazine)Orphan drugNeurocrine Biosciences Inc.
12.1 Mechanism of Action The mechanism of action of valbenazine for the treatment of tardive dyskinesia and chorea in patients with Huntington’s disea...
pingyi xu, Ph.D
First Affiliated Hospital of Guangzhou Medical University
Josef Priller, MD
Charite University, Berlin, Germany
Ira Shoulson, MD
Huntington Study Group/University of Rochester
Pablo Mir Rivera, MD/PhD
Institute of Biomedicine of Seville (IBiS)
📍 San Sebastián, San Sebastian
Steve Whitaker, MD
Omeros Corporation
Steven M Hersch, MD, PhD, MD
Massachusetts General Hospital
📍 BOSTON, MA